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The erythrocyte and plasma fatty acid compositions of children with autism were compared in a case–control study with typically developing (TD)
children and with children showing developmental delay (DD). Forty-five autism subjects were age-matched with TD controls and thirty-eight with
DD controls. Fatty acid data were compared using paired t tests. In addition, blood fatty acids from treatment-naive autism subjects were compared
with autism subjects who had consumed fish oil supplements by two-sample t tests. Relatively few differences were seen between erythrocyte fatty
acids in autism and TD subjects although the former had an increased arachidonic acid (ARA):EPA ratio. This ratio was also increased in plasma
samples from the same children. No changes in n-3 fatty acids or ARA:EPA ratio were seen when comparing autism with DD subjects but some
SFA and MUFA were decreased in the DD subjects, most notably 24 : 0 and 24 : 1, which are essential components of axonal myelin sheaths.
However, if multiple comparisons are taken into account, and a stricter level of significance applied, most of these values would not be significant.
Autism subjects consuming fish oil showed reduced erythrocyte ARA, 22 : 4n-6, 22 : 5n-6 and total n-6 fatty acids and increased EPA, 22 : 5n-3,
22 : 6n-3 and total n-3 fatty acids along with reduced n-6:n-3 and ARA:EPA ratios. Collectively, the autism subjects did not have an underlying
phospholipid disorder, based on erythrocyte fatty acid compositions, although the increased ARA:EPA ratio observed suggested that an imbalance
of essential highly unsaturated fatty acids may be present in a cohort of autism subjects.
Blood fatty acids: Autism: Child health: n-3 Highly unsaturated fatty acids: Fish oils
Autism is a behaviourally defined condition, with no definitive
biomarkers, characterised by impairments in social interactions,
verbal and non-verbal communications, and by restricted and
repetitive stereotypical behaviours. Autism spectrum disorders
are considered to be aetiologically and phenotypically
heterogeneous. Until the mid–late 1980 s autism was a
relatively rare condition with a prevalence of 5–10 per 10 000
of the population. However, over the last 15 years autism rates
have increased such that it is now the most prevalent serious
childhood developmental disorder in the developed world with
a rate in the UK of 1 in 100(1,2). However, there is considerable
debate regarding the reasons for and the extent of the increase,
with some authors claiming that changes are due largely to
widened diagnostic criteria while others claim that the increased
prevalence is a reality and perhaps underestimated(3,4).
Over the past 10 years, a number of behavioural and
learning disorders have been associated with suboptimal
cellular fatty acid status including attention deficit hyperactiv-
ity disorder (ADHD), dyslexia, dyspraxia and autism(5).
Similarly, a number of neurological and neurodegenerative
disorders including schizophrenia, unipolar and bipolar
depression and postnatal depression have been linked to
reduced erythrocyte and plasma fatty acid concentrations
that may be related to changes in lipid metabolism(6).
The principal highly unsaturated fatty acids (HUFA) in
neural tissues are DHA of the n-3 series (22 : 6n-3) and ara-
chidonic acid (20 : 4n-6; ARA) of the n-6 series. The brain
is about 60 % lipid, largely phospholipid (PL), and of this
lipid the majority is made up of DHA and ARA that
together represent more than 20 % of the brain dry weight
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and more than 30 % of retinal weight(7,8). The essential
HUFA, EPA (20 : 5n-3) is not generally enriched in neural
tissues but has significant anti-inflammatory activity due to
its ability to compete with ARA, and attenuate the pro-
duction of ARA-derived eicosanoids in tissues and cell
membranes(8,9). Classically, the essential fatty acids in
humans are regarded as the C18 fatty acids linoleic
(18 : 2n-6) and a-linolenic (18 : 3n-3) acids, although these
require further metabolism by a series of desaturation and
elongation reactions to form their functional HUFA,
namely, ARA, EPA and DHA(10). However, while these
pathways exist in humans the conversion of 18 : 3n-3 to
DHA is very poor, with between 0·05 and 4 % being con-
verted, which suggests that requirements for HUFA will
not be met without significant exogenous supply(11). Interest-
ingly, this conversion is higher in women than men, particu-
larly during pregnancy when conversion efficiency can
increase to 9 %(12,13). This fact may be relevant to the sex
ratio seen in autism where the ratio of prevalence is more
than 4:1 in favour of males(14).
As described above, the fatty acid composition of the
brain and neural tissues is unique with respect to their
high HUFA concentrations. Recently, many functions for
these HUFA have been elucidated including regulation of
signal transduction(15), neuro-inflammation(16) and cellular
repair and survival(17). The cell membrane PL are enriched
in HUFA, especially in the sn-2 position, and these mem-
branes are subject to constant breakdown and re-synthesis
to maintain membrane integrity. The replacement HUFA
for PL synthesis are obtained from the circulating plasma
and may be directly from dietary sources or from the
actions of synthetic pathways in vivo. Recent studies have
found polymorphisms in the gene cluster associated with
the fatty acid desaturase-2 gene (FADS2) for D6-desaturase
in patients with ADHD(18,19). As D6-desaturase is the rate-
limiting step in HUFA synthesis, reduced expression
could reduce HUFA availability and a reduction in cellular
concentrations.
A number of papers have reported changes in erythrocyte
and plasma fatty acids in autism patients. Vancassel et al. (20)
observed significantly reduced n-3 PUFA and an increased
n-6:n-3 ratio in plasma PL from autism patients compared
with those who they designated as intellectually impaired
patients. Similar changes were seen in erythrocyte PL from
children with classical or early-onset and regressive autism
compared with adult controls, although in addition there
were decreased levels of total dimethyl acetals (DMA) and
increased ARA:EPA ratios, 24 : 1 and 22 : 5n-6 in the autism
patients compared with controls(21). Stearic acid (18 : 0),
total SFA and 18 : 2n-6 were significantly increased and
18 : 1n-9, total MUFA and ARA were significantly reduced
in regressive autism patients compared with controls(21).
In addition, erythrocyte type IVA phospholipidase A2
concentrations were significantly higher in both autism
groups compared with adult controls. In a recent study in
California, erythrocyte PL fatty acid compositions were
measured in twenty age-matched patients with regressive
autism, early-onset autism, twenty patients with non-autistic
developmental disabilities and twenty typically developing
(TD) controls(22). Their main findings were increased levels
of 20 : 1n-9 and 22 : 1n-9 in regressive autism subjects
compared with TD controls. In addition, 20 : 2n-6 was
increased and trans-16 : 1n-7 was decreased in patients with
regressive autism compared with early-onset autism
patients(22).
In the present study, it was planned to collect blood
samples from three groups of children, who had respectively
a diagnosis of autism or were developmentally delayed (DD)
or were considered TD. Erythrocyte and plasma PL fatty
acid compositions were measured in all three groups as
well as in a smaller number of patients with autism who
had consumed fish oils in the 6 months before sampling.
The primary hypothesis tested in the present study was
that children with autism have a lipid metabolic disorder
that can be characterised by changes in circulating fatty
acids, and in particular, but not exclusively, by reduced con-
centrations of essential HUFA (ARA, EPA and DHA) in
erythrocyte and plasma PL. In the autism group receiving
fish oil we hoped to establish whether such supplementation
would result in increased membrane levels of the n-3 HUFA
and reduced n-6 HUFA.
Materials and methods
Study participants
A total of 330 children were approached as part of the
present case–control study. Of these, 198 had a diagnosis of
autism, forty-five had DD and eighty-seven were classed as
TD. Of these, forty-nine were recruited for inclusion in the
study from the autism group, thirty-nine in the DD group
and fifty-two in the TD group. Reasons for rejection included:
taking fish oil supplements (thirty-five, two and fourteen
subjects in the autism, DD and TD groups, respectively);
taking steroids (five, one and seven subjects, respectively);
and other reasons (fourteen, three and five subjects, respect-
ively). The autism study participants were either existing
patients of the Royal Hospital for Sick Children (RHSC),
Edinburgh or were recruited from the Lothian National
Health Service (NHS) catchment area. The subjects with
autism met the criteria for autistic disorders by the Autism
Diagnostic Interview – Revised (ADI-R)(23), which is a
comprehensive investigative-based interview that covers
most developmental and behavioural aspects of autism.
The ADI-R has a diagnostic algorithm that maps to both
Diagnostic and Statistical Manual for Mental Disorders, 4th
ed. (DSM-IV) and International Classification of Diseases
10th Revision (ICD-10) criteria for the diagnosis of autistic
disorder. In addition, the diagnosis of autism had been made
by either a Consultant Paediatrician or Child and Adolescent
Psychiatrist according to evidence-based guidelines(24) which
included multidisciplinary specialist assessment, the employ-
ment of a classification system(25,26) and the use of a published
diagnostic instrument(27).
The first control group was of TD children who were
matched on chronological age and who were visiting
outpatient clinics for investigative procedures or undergoing
elective surgery. They donated part of the blood sample
being drawn for routine investigations. These controls
measured within the normal ranges on the Strengths and
Difficulties Questionnaire(28). The second control group
comprised children with learning disabilities and/or
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generalised DD who were matched to the children with
autistic disorder on the Vineland Adaptive Behaviour
Scales(29). Not all cases or controls were able to be matched.
However, thirty-eight pairs of autism cases were age- and
sex-matched with DD controls where the age matching in
this case was done using developmental age as assessed by
Vineland and forty-five pairs of autism cases were age- and
sex-matched to TD controls using chronological age.
In addition to the original research aims, and due to the
high number of children with autism who were taking fish
oil supplements, it was decided to analyse samples from
twenty-one subjects with autism who had taken fish oil and
compare them with the forty-nine autism subjects described
above. The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki and
all procedures involving human patients were approved by
the Lothian Research Ethics Committee (LREC reference
04/S1103/51). Written consent was obtained from all parents.
The sampled population included forty-nine children with
autism, aged 7·5 (SD 3·5) years (89·6 months), including
five females, thirty-nine children with DD, aged 6·0 (SD 3·3)
years (72·2 months), including four females and fifty-two TD
children, aged 7·5 (SD 3·6) years (89·9 months), including
three females.
Blood collection
Whole blood (4 ml) was collected by phlebotomists at
the RHSC Edinburgh, into tubes containing EDTA as anti-
coagulant (Teklab Medical Laboratories, Durham, UK). The
blood was centrifuged (1000 g; 5 min.) and the plasma
removed and retained. In addition, the buffy coat and the
top 2 mm of erythrocytes were removed using a Pasteur
pipette and placed in a separate vial. The remaining packed
erythrocytes were split into two samples and stored at
2708C at the biochemistry laboratories at the RHSC. Samples
were frozen at 2708C in a freezer within 60 min of collecting
the blood sample. Each sample was assigned a numbered code
that was known only to project staff at the RHSC so that
samples were analysed blind by staff at Stirling for polar
lipid fatty acid compositions of erythrocyte and plasma.
Samples were collected from the RHSC every 2 months and
delivered to Stirling on dry ice where they were stored at
2708C until analysed.
Lipid extraction, preparation of phospholipid fraction and
preparation of fatty acid methyl esters in erythrocytes and
plasma
The lipid extraction was a modification of the method of
Bligh & Dyer(30). The erythrocyte pellet was thawed and
0·25–0·50 ml placed in a 15 ml stoppered tube. Then 5 ml
methanol–0·01 % butylated hydroxytoluene (BHT, w/v)
was added and then mixed on a vortex mixer. After
20 min at room temperature 2·5 ml chloroform–BHT was
added, mixed and left at room temperature for a further
40 min. The tubes were centrifuged at 500 g for 5 min and
the supernatant fraction decanted into a clean 15 ml tube
after filtering though Whatman no. 1 paper. A further
2·5 ml chloroform–BHT and 2·5 ml of 0·88 % KCl (w/v)
were added, mixed and centrifuged as above. The lower
chloroform layer was removed and filtered into a 15 ml
tube and evaporated under N2. The lipid was taken up in
0·8 ml chloroform–methanol (2:1, v/v) and placed in a
weighed glass vial. This was dried under N2 and desiccated
for 16 h. After recording the lipid weight the sample was
re-suspended in chloroform–methanol (2:1, v/v) þ BHT, at
a concentration of 10 mg/ml and stored at 2708C until
analysed.
Plasma samples (0·5 ml) were extracted by the method of
Folch et al. (31) in 10 ml chloroform–methanol (2:1, v/v),
washed with 0·88 % KCl (w/v) and filtered and dried
as above. Final lipid extracts were re-suspended in chloro-
form–methanol (2:1, v/v) þ BHT, at a concentration of
10 mg/ml and stored at 2708C until analysed.
A PL fraction was prepared from 0·5 mg of total
lipid applied to a 20 £ 20 cm silica gel 60 TLC plate
(VWR, Lutterworth, Leics, UK) and developed in iso-
hexane–diethyl ether–acetic acid (80:20:1, by vol.) and
dried for a few minutes at room temperature. The plate
was sprayed lightly with 2, 7, dichlorofluorescein (0·1 %,
w/v) in 97 % methanol (v/v) and the PL bands on the
origin scraped from the plate and placed in a 15 ml test-
tube. Fatty acid methyl esters (FAME) were prepared by
acid-catalysed transesterification in 2 ml of 1 % H2SO4 in
methanol at 508C overnight(32). The samples were neutralised
with 2·5 ml of 2 % KHCO3 and extracted with 5 ml isohex-
ane–diethyl ether (1:1, v/v) þ BHT. The samples were then
re-extracted with 5 ml isohexane–diethyl ether (1:1, v/v)
and the combined extracts dried and dissolved in 0·3 ml
isohexane before fatty acid analysis.
Measurement of erythrocytes and plasma fatty acids
FAME were separated and quantified by GLC (Fisons 8160;
Carlo Erba, Milan, Italy) using a 60 m £ 0·32 mm £ 0·25mm
film thickness capillary column (ZB-WAX; Phenomenex,
Macclesfield, Cheshire, UK). H2 was used as the carrier
gas at a flow rate of 4·0 ml/min and the temperature pro-
gramme was from 50 to 1508C at 408C/min then to 1958C
at 28C/min and finally to 2158C at 0·58C/min. Individual
FAME were identified compared with well-characterised in-
house standards as well as commercial FAME mixtures
(Supelcoe 37 FAME mix; Sigma-Aldrich Ltd, Gillingham,
Dorset, UK).
Statistical analysis
To determine if there were any differences between fatty acid
compositions in autism cases and age- and sex-matched TD
controls, or DD controls, paired t tests were used. To com-
pare the fatty acid compositions of the autism group (n 49)
with autism patients who were excluded from the main
trial due to consumption of fish oils (n 21) a two-sample
t test was used. The level of significance was set initially
at P,0·05.
Results
In total, 330 children were identified from the Lothian
National Health Service (NHS) trust catchment as being
potential participants in the present study. Of these, 140
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children agreed or were suitable for participation. The reasons
for non-suitability were varied and included consumption of
fish oil supplements in the previous 6 months and taking
steroids. The percentage of participants already consuming
fish oils represented 18 % of the autism group, 16 % of the
TD group and 4 % of the DD group.
When comparing the erythrocyte polar lipid fatty acid data
of the autism and TD groups (Table 1) only a few fatty acids
or ratios were different (P,0·05). a-Linolenic acid (18 : 3n-3),
the precursor for the longer-chain n-3 HUFA, was reduced in
the autism group compared with the TD group while the
ARA:EPA ratio was increased. The plasma polar lipid fatty
acid compositions in the pair-matched autism and TD
groups showed very few differences (Table 1). The minor
SFA 14 : 0 and 15 : 0 were reduced while the n-6:n-3 and
ARA:EPA ratios were increased in the autism group compared
with the TD group.
When comparing the erythrocyte polar lipid fatty acid
data between pair-matched children from the autism and
DD groups (Table 2) the SFA 20 : 0, 22 : 0 and 24 : 0 as well
as the MUFA 16 : 1n-9, 20 : 1n-9, 22 : 1n-9 and 24 : 1n-9
were all increased in the autism group compared with
the DD group. In addition, the 18 : 1n-7 DMA fatty acid
was increased in the autism group compared with the DD
group. By comparison, the total n-6 fatty acids and the total
PUFA were reduced in the autism group compared with the
DD group.
Relatively minor changes were also seen in the plasma polar
lipid fatty acid compositions when comparing pair-matched
autism and DD subjects (Table 2). The SFA 20 : 0 and total
saturates were reduced in the autism compared with the DD
group while 18 : 1n-9 DMA and total DMA were increased
in the autism group compared with the DD group.
The erythrocyte polar lipid fatty acid compositions in
autism patients compared, using two-sample t tests, with
autism patients who had consumed fish oil supplements
showed a number of differences between treatment groups
(Table 3). Of the twenty-one autism patients who had
consumed fish oils, fifteen had taken Eye Qe (Equazer,
Wallingford, Oxfordshire, UK), one had taken Haliborange-3
(Seven Seas Ltd, Hull, UK) and one had taken Eskimo-3w
(Whaley Bridge, Derbyshire, UK) while four did not specify
the fish oil product. Among the MUFA, 18 : 1n-7 was
decreased in the autism compared with the autism þ fish oil
group. In the n-6 fatty acids, ARA, 22 : 4n-6 and 22 : 5n-6
were reduced in the autism þ fish oil group compared with
the autism group. The reductions in n-6 HUFA were reversed
in the n-3 HUFA which had increased EPA, 22 : 5n-3, DHA
and total n-3 HUFA in the autism þ fish oil group compared
with the autism group. In addition, the n-6:n-3 ratio and the
ARA:EPA ratio were both reduced in the autism þ fish oil
group compared with the autism group (Table 3).
The plasma polar lipid fatty acid compositions in autism
patients compared, using two-sample t tests, with autism
patients who had consumed fish oil supplements showed a
number of differences similar to those seen in the erythrocyte
data described above (Table 3). The MUFA 18 : 1n-7
was increased, as seen in erythrocytes, but 18 : 1n-9 and
20 : 1n-9 were decreased and increased, respectively, in the
autism þ fish oil group. ARA was not different in plasma
Table 1. Fatty acid compositions of erythrocyte and plasma polar lipids (weight % of total fatty acids) in autism and typically
developing (TD) subject groups (n 45, pair-matched)
(Mean values and standard deviations)
Erythrocytes Plasma
Autism TD Autism TD
Fatty acids Mean SD Mean SD P Mean SD Mean SD P
Saturates
14 : 0 0·32 0·13 0·36 0·11 0·093 0·34 0·14 0·44 0·13 0·001*
15 : 0 0·19 0·06 0·21 0·05 0·227 0·20 0·07 0·25 0·07 0·004*
Total saturates 39·33 1·69 39·55 1·38 0·527 42·23 1·37 42·69 1·21 0·102
Monoenes
20 : 1n-9 0·35 0·08 0·33 0·07 0·398 0·20 0·07 0·23 0·10 0·068
24 : 1n-9 2·15 0·41 2·00 0·29 0·082 0·95 0·26 1·02 0·26 0·141
Total monoenes 17·27 1·59 16·86 1·04 0·161 14·84 2·33 14·63 1·82 0·632
n-6
18 : 2n-6 11·58 1·44 11·49 1·47 0·793 21·45 3·24 21·01 2·72 0·490
20 : 4n-6 13·52 1·15 13·51 1·15 0·953 10·15 1·67 9·96 1·44 0·605
22 : 4n-6 2·61 0·43 2·52 0·43 0·369 0·48 0·10 0·45 0·10 0·213
22 : 5n-6 0·55 0·13 0·53 0·13 0·411 0·27 0·10 0·25 0·08 0·204
Total n-6 30·76 1·69 30·51 1·41 0·501 36·13 2·61 35·5 2·39 0·211
n-3
18 : 3n-3 0·15 0·06 0·20 0·13 0·042* 0·19 0·10 0·23 0·10 0·051
20 : 5n-3 0·53 0·24 0·58 0·20 0·317 0·60 0·29 0·69 0·32 0·184
22 : 5n-3 2·01 0·44 2·10 0·27 0·251 0·94 0·22 0·96 0·15 0·553
22 : 6n-3 3·30 1·04 3·61 0·93 0·138 2·58 0·78 2·81 0·72 0·153
Total n-3 6·04 1·34 6·53 1·24 0·077 4·39 1·06 4·80 1·03 0·079
Total PUFA 36·79 1·76 37·04 1·63 0·499 40·52 2·43 40·29 2·13 0·618
n-6:n-3 5·39 1·42 4·86 1·04 0·054 8·79 2·56 7·75 1·82 0·035*
20 : 4n-6:20 : 5n-3 31·69 17·40 25·98 8·21 0·047* 22·95 15·88 16·96 6·69 0·021*
*P,0·05.
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but 22 : 4n-6, 22 : 5n-6 and total n-6 fatty acids were all
reduced in the autism þ fish oil group while 18 : 3n-3,
20 : 4n-3, EPA, 22 : 5n-3, DHA and total n-3 fatty acids were
all increased in the autism þ fish oil group (Table 3). As in
erythrocytes, the n-6:n-3 and ARA:EPA ratios were both
decreased in the autism þ fish oil group compared with the
autism group.
Discussion
The results of the present study do not suggest that the autism
population in general have a problem with abnormal PL
metabolism although there are subtle changes in specific
fatty acids and ratios that might indicate problems with
some individuals in the study groups. While we initially set
the level of significance at P,0·05 this would not take
account of multiple comparisons and, thus, if a stricter level
of significance set at P,0·0025 were applied then most of
the values presented in Tables 1–3 would not be significant.
Correction for multiple comparisons prevents accidental
significance being assigned when combining and comparing
data from unrelated sources, for example, data from different
tissue or cell types. However, when considering membrane
fatty acid analysis from one cell type or plasma fraction,
a level of significance set at P,0·0025 is probably not necess-
ary. This is supported by studies in the literature involving
fatty acid datasets from similar pair-matched studies(22,33,34).
The most notable difference between the erythrocyte fatty
acids from the autism and TD study groups was an increased
ARA:EPA ratio in the former. A similar increase in this ratio
was also seen in plasma PL fatty acids in the autism group
compared with the TD group. This increased ratio was also
seen in an earlier study where children with autism were
compared with adolescent and adult controls(21) but no
difference in the ARA:EPA ratio was seen in the study by
Bu et al. (22). In the latter, the mean erythrocyte ARA:EPA
ratio varied from 66 to 72 which is much higher than the
values of 23 and 17 seen in the autism and TD groups in
the present study. This may be due to higher n-6 PUFA
intake, relative to n-3 PUFA, in the US diet or perhaps
differences in methodology used in the two studies. By
comparison, the ARA:EPA ratio in two different groups of
UK adults, conducted in our own laboratories in 2006–7,
was 15·8 and 16·7(35) (JG Bell, EE MacKinlay and JR Dick,
unpublished results).
ARA and EPA are competitive substrates for the production
of eicosanoids, including, inter alia, PG, thromboxanes and
leukotrienes (LT) that are involved in the generation and
modulation of inflammatory responses(36). Compared with
ARA, EPA is less favoured for eicosanoid synthesis by the
cyclo-oxygenase and lipoxygenase enzymes that generate
PG and LT, respectively, but EPA can inhibit production of
the more bioactive PG and LT at a number of steps in their
synthetic pathways(37,38). Thus, the dietary balance of n-6
and n-3 fatty acid intake can affect the concentration and
bioactivity of these cellular mediators. The tissue ARA:EPA
ratio is regarded as an inflammatory index since ARA
produces eicosanoids that stimulate aggregation and
Table 2. Fatty acid compositions of erythrocyte and plasma polar lipids (weight % of total fatty acids) in autism and developmental
delay (DD) subject groups (n 38, pair-matched)
(Mean values and standard deviations)
Erythrocytes Plasma
Autism DD Autism DD
Fatty acids Mean SD Mean SD P Mean SD Mean SD P
Saturates
20 : 0 0·27 0·04 0·24 0·04 0·020* 0·28 0·08 0·32 0·06 0·022*
22 : 0 0·89 0·14 0·77 0·11 0·002* 0·65 0·19 0·73 0·18 0·066
24 : 0 1·99 0·31 1·79 0·25 0·004* 0·54 0·17 0·59 0·16 0·135
Total saturates 39·15 1·54 38·72 1·29 0·230 42·32 1·32 42·90 1·02 0·047
Monoenes
16 : 1n-9 0·14 0·06 0·19 0·08 0·007* 0·25 0·09 0·24 0·07 0·333
20 : 1n-9 0·35 0·09 0·30 0·07 0·013* 0·19 0·07 0·18 0·03 0·215
22 : 1n-9 0·05 0·02 0·03 0·02 0·004* ,LOQ ,LOQ
24 : 1n-9 2·17 0·39 1·89 0·30 0·002* 0·95 0·24 1·00 0·23 0·348
Total monoenes 17·27 1·63 16·77 1·24 0·108 14·70 2·33 15·01 1·80 0·500
n-6
20 : 4n-6 13·63 1·15 14·04 1·20 0·151 10·27 1·58 10·41 1·68 0·705
22 : 5n-6 0·56 0·13 0·62 0·14 0·080 0·28 0·11 0·31 0·11 0·149
Total n-6 30·85 1·57 31·63 1·79 0·027* 36·31 2·19 35·49 2·40 0·142
n-3
20 : 5n-3 0·51 0·22 0·54 0·22 0·566 0·58 0·28 0·60 0·26 0·639
22 : 6n-3 3·36 1·07 3·36 0·95 0·987 2·56 0·80 2·57 0·80 0·961
Total n-3 6·06 1·41 6·10 1·30 0·885 4·31 1·03 4·41 1·07 0·663
18 : 1n-9 DMA 0·91 0·35 0·98 0·49 0·435 0·29 0·17 0·22 0·06 0·008*
18 : 1n-7 DMA 0·18 0·09 0·13 0·15 0·003* ,LOQ ,LOQ
Total DMA 6·67 0·52 6·77 0·47 0·332 2·39 0·48 2·19 0·33 0·044*
Total PUFA 36·91 1·78 37·73 1·63 0·025* 40·62 2·20 39·9 2·12 0·176
20 : 4n-6:20 : 5n-3 32·74 18·31 29·68 9·65 0·318 23·93 16·82 20·15 7·79 0·191
LOQ, limit of quantification; DMA, dimethyl acetals.
*P,0·05.
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inflammatory responses via 2-series PG and 4-series LT while
the 3-series PG/5-series LT, derived from EPA, have opposing
activities(39).
Comparing the erythrocyte PL fatty acids in autism and DD
groups, the latter had reduced concentrations of 20 : 0, 22 : 0,
24 : 0, 20 : 1n-9, 22 : 1n-9, 24 : 1n-9 and 18 : 1n-7 DMA and
increased concentrations of total n-6 fatty acids and total
PUFA, compared with the autism group. The long-chain
fatty acids 24 : 0 and 24 : 1n-9 are important components of
myelinated nerve axons and synapses in brain white matter
where they can comprise up to 48 and 16 % of fatty acids in
glyco- and sphingolipids, respectively(40). Thus, these changes
may reflect suboptimal myelin development amongst the DD
children. The reductions in 20 : 0, 22 : 0, 20 : 1n-9 and
22 : 1n-9 might indicate that these fatty acids are being utilised
to synthesise 24 : 0 and 24 : 1n-9 in the DD group. The study
by Bu et al. (22) observed an increase in 20 : 1n-9 and
22 : 1n-9 in patients with regressive autism compared with
TD controls. These MUFA are minor components of
membrane lipids but are found at higher levels in neutral
lipids where they are substrates for energy production by
b-oxidation. It was suggested(22) that this elevation of
MUFA might reflect an impairment in this energy production
pathway as seen in patients with mitochondrial dysfunction
which has been recorded in psychiatric disorders, including
autism(41,42). However, a similar elevation was not observed
in the present study.
The final part of the present study compared treatment-naive
autism patients with autism patients who had taken fish oil
supplements over the previous 6 months. Of the n-6 fatty
acids, ARA, 22 : 4n-6, 22 : 5n-6 and total n-6 PUFA were
reduced in fish oil-supplemented patients compared with the
unsupplemented group. The reduction in ARA and its
elongation–desaturation products in the fish oil-supplemented
group is due to competition between EPA and ARA for the
sn-2 position on PL, displacement of ARA by EPA and
reduced synthesis of C22 HUFA. This is seen in most studies
with EPA-rich supplements(43,44). In the erythrocyte n-3 fatty
acids, fish oil intake increased EPA, 22 : 5n-3, DHA and total
n-3 fatty acids and reduced n-6:n-3 and ARA:EPA ratios.
As with the reductions in n-6 HUFA, these changes in n-3
fatty acids are similar to those recorded in other studies using
fish oil supplementation(43,44,45).
The changes in plasma fatty acids in autism patients who
took fish oil were similar to those in erythrocytes, except
that ARA was not reduced. In ADHD patients given fish oil,
plasma ARA remained unchanged or increased following
supplementation(45,46). Of the n-3 fatty acids, the same fatty
acids were increased and decreased as in erythrocytes but
18 : 3n-3, 20 : 4n-3 and total PUFA were also increased,
reflecting the abundance of these fatty acids in fish oil.
These changes are consistent with other studies where patients
have taken fish oil supplements including schizophrenia,
ADHD, cystic fibrosis and autism(21,43,45,47).
The relatively minor changes observed in erythrocytes and
plasma fatty acids in children with autism compared with
TD children does not support a general ‘phospholipid
spectrum disorder’ in the autism population. Similarly, there
is no evidence, based on the results of the present study,
for providing all autism patients with fish oil supplements.
Table 3. Fatty acid compositions of erythrocyte and plasma polar lipids (weight % of total fatty acids) in patients with autism who met
the agreed participation criteria compared with those excluded due to consumption of fish oil supplements in the preceding 6 months†
(Mean values and standard deviations)
Erythrocytes Plasma
Autism (n 49)
Autism þ fish
oil (n 21) Autism (n 49)
Autism þ fish
oil (n 21)
Fatty acids Mean SD Mean SD P Mean SD Mean SD P
Total saturates 39·26 1·64 39·81 1·69 0·217 42·24 1·32 41·73 2·10 0·316
Monoenes
18 : 1n-9 12·97 1·36 12·72 1·05 0·417 11·53 2·15 10·52 1·64 0·036*
18 : 1n-7 1·27 0·18 1·47 0·28 0·005* 1·38 0·22 1·52 0·27 0·045*
20 : 1n-9 0·34 0·08 0·33 0·09 0·437 0·20 0·07 0·28 0·08 0·0002*
24 : 1n-9 2·15 0·39 1·99 0·39 0·139 0·97 0·26 0·99 0·31 0·776
Total monoenes 17·28 1·53 17·02 1·09 0·435 14·89 2·25 14·10 1·66 0·112
n-6
20 : 4n-6 13·62 1·17 12·29 1·38 0·0005* 10·19 1·64 9·83 1·69 0·413
22 : 4n-6 2·61 0·40 2·02 0·38 ,0·0001* 0·48 0·10 0·38 0·11 0·0007*
22 : 5n-6 0·56 0·13 0·38 0·12 ,0·0001* 0·27 0·10 0·18 0·08 0·0002*
Total n-6 30·73 1·61 28·36 2·29 0·0002* 36·05 2·50 34·53 2·78 0·037*
n-3
18 : 3n-3 0·15 0·05 0·18 0·06 0·130 0·19 0·10 0·28 0·09 0·001*
20 : 4n-3 0·05 0·04 0·06 0·04 0·372 0·09 0·07 0·14 0·08 0·025*
20 : 5n-3 0·53 0·23 1·09 0·61 0·0005* 0·61 0·29 1·40 1·00 0·002*
22 : 5n-3 2·01 0·42 2·29 0·46 0·022* 0·94 0·22 1·16 0·33 0·008*
22 : 6n-3 3·34 1·01 4·54 1·24 0·0005* 2·57 0·75 3·93 1·27 0·0001*
Total n-3 6·08 1·30 8·15 1·74 ,0·0001* 4·40 1·02 6·91 2·03 ,0·0001*
Total PUFA 36·81 1·70 36·51 2·02 0·548 40·46 1·34 41·43 2·21 0·071
n-6:n-3 5·33 1·37 3·70 1·18 ,0·0001* 8·70 2·45 5·47 1·85 ,0·0001*
20 : 4n-6:20 : 5n-3 31·15 16·60 14·46 7·97 ,0·0001* 22·21 15·25 9·18 4·82 ,0·0001*
*P,0·05.
† Two-sample t test comparing autism (n 49) with autism patients who were taking fish oil supplements (n 21).
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However, a number of noteworthy points arose from the
present study. First, there was a relative reduction in n-3
fatty acids and/or a relative increase in n-6 fatty acids in the
autism population compared with TD children, as evidenced
by the increased ARA:EPA ratio in the former. The ranges
for this ratio in the autism and TD groups, 11·2–100·2 and
11·8–46·8, respectively, suggests there are children in the
autism group with very high ratios that may indicate problems
in addition to poor dietary intake. We were not able to obtain a
prospective dietary history from the children in the study
because ethically we had to obtain an opportunistic blood
sample from the children in the control group. If we had
chosen to gather this information from the children in the
autism group in advance of the blood sampling, then we
may have introduced confounders by drawing the families’
attention to the HUFA content of their child’s diet. However,
recent work by Herndon et al. (48) suggests that children with
autism differ from controls in their lower intake of dairy
products and Ca and so it would appear that whilst we
cannot discount a possible contribution of diet, this is unlikely
to fully explain the differences seen. It was also apparent that
the n-3 HUFA in all the groups studied were significantly
lower than values reported in UK adults(21,35). There is also
evidence that n-3 HUFA are significantly higher in neonates
and infants(49,50) compared with the children in the present
study. However, we do not know whether levels in children
would be expected to be lower than those in infancy and
adult life but the fact that they rose to similar levels following
supplementation suggests that the levels are suboptimal.
In addition, autism patients given fish oil had erythrocyte
DHA levels which were similar to both UK adult and neonate
values. Therefore, when we compare these findings with
animal studies, and n-3 HUFA in neural development in
young humans(8,9,39), the low levels seen in Scottish children
in the present study are concerning. Whilst the evidence for
efficacy of HUFA supplementation in conditions such as
autism and ADHD still needs to be fully delineated(51), we
have demonstrated that it is effective at a biochemical level
in promoting what is generally considered to be a more
optimal ratio(34,45,46,52,53). Future studies should consider
these areas as well as using molecular techniques to establish
whether specific problems with HUFA retention and
metabolism exist in a cohort of children with autism.
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